As a typical representative of China's innovation hub, Hangzhou is leading the country's innovation trend with its unique technology ecosystem and rapidly developing digital economy. Numerous tech companies with strong R&D capabilities have emerged here, making it an important testing ground for cutting-edge fields such as biomedicine, artificial intelligence, and big data. Meanwhile, the rapid rise of frontier technologies like DeepSeek, a large language model developed in China, has also secured Hangzhou's undeniable position on the global technology map, showcasing China’s immense potential and vitality in technological innovation in the new era.

On February 22, 2025, Forbes China released the "2024 Forbes China New Sharp Innovators & Entrepreneurs" list in Hangzhou. Dr. Lai Caida, co-founder and CEO of METiS TechBio, was honored on the list.The Increasingly Mature and Diversified Development of China's Innovation Ecosystem — In an era where AI, pharmaceuticals, and internet technologies converge, every field is writing new legends.

Empowering Drug Discovery with AI, Unveiling a New Era of Intelligent Healthcare

With the rapid development of large AI models, from the rise of domestically produced models like DeepSeek to the widespread application of AI in protein structure prediction, molecular design, and delivery optimization, AI-driven pharmaceutical innovation is entering a golden age.Led by Dr. Lai Caida, "Development of mRNA Therapies for Acute and Chronic Liver Diseases Based on AI + Nucleic Acid Drug Design and Delivery PlatformThe project has been included in the major technological breakthrough project of the National Biopharmaceutical Technology Innovation Center's "Nucleic Acid Drug Challenge." Additionally, he has been selected for several prestigious lists, including Fortune China's 40 Under 40 Business Elites in 2024, 36Kr's "36Under36 Scientists," and the Hurun China Healthcare Young Entrepreneurs list in 2024.

Moreover, the core team of METiS TechBio brings together top interdisciplinary talents from both China and the U.S. in the fields of AI, drug delivery, and R&D, forming an international "dream team" that understands both AI and drug development.

As an outstanding representative of Hangzhou's AI + hard technology, METiS TechBio will continue to deepen the integration and innovation of AI and biomedicine. By leveraging advanced large models and self-developed AI technologies, it aims to promote the intelligent upgrade of new drug research and development, accelerate breakthroughs in the global biopharmaceutical industry’s technological boundaries, and bring more transformative treatment solutions to patients.

-- END --

METiS TechBio Awarded "National High-Tech Enterprise" Recognition